Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development

03 Nov 2026 0 comments

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

Source: NeurologyLive Published 03 Nov 2026 Imported 03 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment